StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)

Close on Nov 17, 2026Market cap $1.78BP/E –Yield –

Agios Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Agios Pharmaceuticals's cash was $1.00B at Jun 30, 2026. For fiscal 2025 it was $1.20B, down 20.0% from the year before. Over ten years it grew 12.3% a year on average. The highest annual figure on record is $1.50B in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.20B-20.0%
FY2024Dec 31, 2024$1.50B+86.0%
FY2023Dec 31, 2023$806.40M-26.7%
FY2022Dec 31, 2022$1.10B-14.5%
FY2021Dec 31, 2021$1.29B+91.9%
FY2020Dec 31, 2020$670.50M-6.6%
FY2019Dec 31, 2019$717.80M-10.9%
FY2018Dec 31, 2018$805.40M+41.8%
FY2017Dec 31, 2017$567.80M-1.0%
FY2016Dec 31, 2016$573.60M+52.6%
FY2015Dec 31, 2015$375.90M-19.6%
FY2014Dec 31, 2014$467.40M+141.1%
FY2013Dec 31, 2013$193.90M+51.5%
FY2012Dec 31, 2012$127.98M+8.8%
FY2011Dec 31, 2011$117.66M+51.1%
FY2010Dec 31, 2010$77.88M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.00B-23.1%
Q1 FY2026Mar 31, 2026$1.00B-28.6%
Q4 FY2025Dec 31, 2025$1.20B-20.0%
Q3 FY2025Sep 30, 2025$1.30B-23.5%
Q2 FY2025Jun 30, 2025$1.30B+101.5%
Q1 FY2025Mar 31, 2025$1.40B+96.0%
Q4 FY2024Dec 31, 2024$1.50B+86.0%
Q3 FY2024Sep 30, 2024$1.70B+94.9%
Q2 FY2024Jun 30, 2024$645.30M-31.9%
Q1 FY2024Mar 31, 2024$714.30M-28.6%
Q4 FY2023Dec 31, 2023$806.40M-26.7%
Q3 FY2023Sep 30, 2023$872.40M-12.8%
Q2 FY2023Jun 30, 2023$946.90M-13.9%
Q1 FY2023Mar 31, 2023$1.00B-16.7%
Q4 FY2022Dec 31, 2022$1.10B-14.5%
Q3 FY2022Sep 30, 2022$1.00B-28.6%
Q2 FY2022Jun 30, 2022$1.10B-35.3%
Q1 FY2022Mar 31, 2022$1.20B-50.0%
Q4 FY2021Dec 31, 2021$1.29B+91.9%
Q3 FY2021Sep 30, 2021$1.40B+93.8%
Q2 FY2021Jun 30, 2021$1.70B+114.0%
Q1 FY2021Mar 31, 2021$2.40B+291.5%
Q4 FY2020Dec 31, 2020$670.50M-6.6%
Q3 FY2020Sep 30, 2020$722.40M+33.7%
Q2 FY2020Jun 30, 2020$794.40M+27.3%
Q1 FY2020Mar 31, 2020$613.10M-13.4%
Q4 FY2019Dec 31, 2019$717.80M-10.9%
Q3 FY2019Sep 30, 2019$540.50M-38.5%
Q2 FY2019Jun 30, 2019$624.00M-33.4%
Q1 FY2019Mar 31, 2019$707.80M-28.8%
Q4 FY2018Dec 31, 2018$805.40M+41.8%
Q3 FY2018Sep 30, 2018$878.40M+561.7%
Q2 FY2018Jun 30, 2018$936.60M+575.2%
Q1 FY2018Mar 31, 2018$994.70M+396.7%
Q4 FY2017Dec 31, 2017$567.80M-1.0%
Q3 FY2017Sep 30, 2017$132.74M-77.1%
Q2 FY2017Jun 30, 2017$138.72M–
Q1 FY2017Mar 31, 2017$200.28M–
Q4 FY2016Dec 31, 2016$573.60M–
Q3 FY2016Sep 30, 2016$579.10M–

More Agios Pharmaceuticals figures

See a number that looks wrong?